Krystal Biotech's earnings call highlights strong financial performance and strategic global expansion, with significant revenue growth and profitability. However, challenges such as anticipated revenue decline in Q3, ongoing sales force scaling, and potential market entry delays in Europe and Japan present concerns.

Company Guidance

During the Krystal Biotech Q2 2025 earnings call, the company provided guidance on several key metrics. Krystal reported a net product revenue of $96 million for VYJUVEK, contributing to a total net revenue of over $525 million since its launch. The company achieved an earnings per share (EPS) of $1.29 fully diluted, marking two years of consistent positive EPS. The compliance rate for patients on VYJUVEK was reported at 82%, with an expectation of a downward trend as severe patients achieve durable wound closure. The company anticipates a temporary decline in Q3 revenues due to summer pauses, with a return to growth in Q4 driven by patient restarts and sales force expansion. Krystal highlighted its global expansion plans, with upcoming launches in Europe and Japan, and maintained a strong financial position with over $820 million in cash and investments.

Strong Revenue Growth for VYJUVEK

Q2 net VYJUVEK revenue was $96 million, with total net revenue since launch exceeding $525 million. The company achieved a 9% growth over the first quarter of 2025.

Global Expansion Milestones

Approval of VYJUVEK by Japan's Ministry of Health and plans for European launch in Germany and France. The company has established dedicated commercial teams in both countries.

Positive Financial Performance

Continued profitability with $1.29 per diluted share, marking two years of consistently positive EPS. Net income for the quarter was $38.3 million.

Pipeline Progress

Clinical data updates for oncology and aesthetic programs, progression of KB408 into repeat dosing for AATD, and new study starts for lung and eye diseases.

Krystal Biotech (KRYS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KRYS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	1.09 / -	0.91	―	―	―
Aug 04, 2025	2025 (Q2)	1.19 / 1.29	0.53	143.40% (+0.76)
May 06, 2025	2025 (Q1)	1.43 / 1.20	0.03	3900.00% (+1.17)
Feb 19, 2025	2024 (Q4)	1.18 / 1.52	0.3	406.67% (+1.22)
Nov 04, 2024	2024 (Q3)	0.99 / 0.91	2.79	-67.38% (-1.88)
Aug 05, 2024	2024 (Q2)	0.73 / 0.53	-1.25	142.40% (+1.78)
May 06, 2024	2024 (Q1)	0.27 / 0.03	-1.76	101.70% (+1.79)
Feb 26, 2024	2023 (Q4)	-0.31 / 0.30	-1.25	124.00% (+1.55)
Nov 06, 2023	2023 (Q3)	-1.20 / 2.79	-1.17	338.46% (+3.96)	―
Aug 07, 2023	2023 (Q2)	-1.26 / -1.25	-1.1	-13.64% (-0.15)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KRYS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$156.98	$134.94	-14.04%
May 06, 2025	$162.29	$139.47	-14.06%
Feb 19, 2025	$156.69	$176.17	+12.43%
Nov 04, 2024	$176.39	$170.85	-3.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Krystal Biotech (KRYS) report earnings?

Krystal Biotech (KRYS) is schdueled to report earning on Nov 10, 2025, Before Open (Confirmed).

What is Krystal Biotech (KRYS) earnings time?

Krystal Biotech (KRYS) earnings time is at Nov 10, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KRYS EPS forecast?

KRYS EPS forecast for the fiscal quarter 2025 (Q3) is 1.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing